Descriptive only

Kidney composite including albuminuria or smaller eGFR declines

Type 2 diabetes (adults)

longest follow-upCause specific hazardsDoses of a drug pooledHazard ratio

Randomized trials

Treatments

Participants

Trial arms

In plain language

No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 1 trial. The trial data below are shown as reported.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.

Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Baseline characteristics of the trials

The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.

Baseline effect modifiers and prognostic factors per trial
Trial	Kidney function (eGFR) (mL/min/1.73 m2) prognostic factor, effect modifier; 1 of 1	Albuminuria (mg/g) prognostic factor; 0 of 1
SUSTAIN™ 6 S001933	76.15	not reported

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.

FlagBaseline, Albuminuria: not reported by 1 of 1 trials

Comparability items per trial
Trial	time weeks	analysis set	definition	instrument	adjudicated	proportion method	intercurrent events (discontinuation)	intercurrent events (rescue)	blinding	funding	start year	Eligibility
SUSTAIN™ 6	109	full_analysis	new or persistent macroalbuminuria, doubling of serum creatinine with creatinine clearance below 45, end stage kidney disease or kidney death	not stated	yes	not stated	not stated	not stated	double_blind	industry	2013	T2D HbA1c 7.0 or more; age 50 or more with CVD, CHF or CKD stage 3 or more, or age 60 or more with CV risk factor

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.

Trial data entering this analysis
Trial	Arm	Treatment	Week	Data	Value	SE	Events / N	Flags	Source
SUSTAIN™ 6	A5	SEMA_SC	109	contrast, hr	-0.446	0.165			R0020578:Introduction
SUSTAIN™ 6	A6	PLACEBO	109	contrast, hr					R0020578:Introduction

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab